Emerging Pharmacological Insights and Therapeutic Prospects of Cynodon dactylon (L.) Pers
Journal of Medicinal Chemistry and Therapeutics · 27.03.2026 · 2 (01) · 1-11
DOI: 10.71193/jmct.20250010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry and Therapeutics, online erschienen am 27.03.2026. Verfasst von Ajay Kumar Verma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Cynodon dactylon (L.) Pers., commonly known as Bermuda grass or "Dhub," is a medicinal herb widely used in Ayurvedic and traditional systems for managing chronic illnesses, diabetes, infections, and inflammatory conditions. Its diverse phytochemical profile comprising terpenoids, anthocyanins, phenolic acids, alkaloids, and flavonoids has drawn growing pharmacological interest.
Objective
This review systematically compiles and evaluates recent in vitro, in vivo, and limited clinical evidence regarding the phytochemical composition and pharmacological properties of C. dactylon, with emphasis on its bioactive constituents, molecular mechanisms, and translational potential, i.e., its ability to progress from experimental findings to standardised therapeutic formulations and future clinical applications. Mechanism: The therapeutic effects of C. dactylon are mediated through modulation of key molecular pathways, including antioxidant defence (enhancement of CAT, SOD, GPx), anti-inflammatory signalling (downregulation of TNF-α, CRP, and nitric oxide pathways), metabolic regulation (inhibition of α-glucosidase and improved glucose uptake), and angiogenic signalling (upregulation of VEGF). These effects are primarily attributed to flavonoids such as apigenin, luteolin, orientin, and vitexin. Key Findings: A comprehensive literature review (PubMed, Scopus, ScienceDirect, Google Scholar; 1990–2025) reveals potent antioxidant, anticancer, antidiabetic, anti-inflammatory, immunomodulatory, antimicrobial, wound-healing, and angiogenic activities across multiple preclinical models.
Conclusion
Despite robust preclinical evidence, significant gaps remain in extract standardisation, mechanistic depth, pharmacokinetics, and clinical validation. Future research should prioritise molecular-level investigations, rigorously designed clinical trials, and advanced delivery systems such as nanoformulations and biomaterial scaffolds. Overall, C. dactylon is a promising phytotherapeutic candidate with meaningful potential to bridge traditional medicine and modern drug development.
Zitieren
APA
Verma, A. K. (2026). Emerging Pharmacological Insights and Therapeutic Prospects of Cynodon dactylon (L.) Pers. Journal of Medicinal Chemistry and Therapeutics, 2(01), 1-11. https://doi.org/10.71193/jmct.20250010
Vancouver
Verma AK. Emerging Pharmacological Insights and Therapeutic Prospects of Cynodon dactylon (L.) Pers. Journal of Medicinal Chemistry and Therapeutics. 2026;2(01):1-11. doi:10.71193/jmct.20250010
BibTeX
@article{Verma2026,
author = {Verma, Ajay Kumar},
title = {Emerging Pharmacological Insights and Therapeutic Prospects of Cynodon dactylon (L.) Pers},
journal = {Journal of Medicinal Chemistry and Therapeutics},
year = {2026},
volume = {2},
number = {01},
pages = {1--11},
doi = {10.71193/jmct.20250010}
}
EUVIMED